Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1NET 1Endocrine 1CNS 1Breast 1

Conditions

Breast Neoplasms 6Neoplasm Metastasis 2Triple Negative Breast Neoplasms 1Pancreatic Neoplasms 1Neoplasms 1Hamartoma Syndrome, Multiple 1Carcinoma, Renal Cell 1Breast Diseases 1

Interventions

Paclitaxel 26pembrolizumab 24Docetaxel 20Capecitabine 19Fulvestrant 17Trastuzumab 16Anastrozole 15Cyclophosphamide 14Lapatinib 13Letrozole 11Carboplatin 11Radiotherapy 10Doxorubicin 10palbociclib 9Therapeutics 9Nivolumab 9Exercise 9Gemcitabine 8Cisplatin 8Blood Specimen Collection 8Tamoxifen 7Bevacizumab 7liposomal doxorubicin 6exemestane 6abemaciclib 6Vinorelbine 6Standard of Care 6Fluorouracil 6atezolizumab 5Surveys and Questionnaires 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × dactolisib × Breast × Clear all
NCT00620594 2020-12-09

A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer

Novartis

Phase 1 Completed
183 enrolled
Breast

Breast Diseases, Breast Neoplasms, Hamartoma Syndrome, Multiple, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡